Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,477 total articles
Taysha Gene Therapies (TSHA) is a clinical-stage AAV gene therapy company whose lead program TSHA-102 for Rett syndrome is approaching a likely interim analysis in the first half of 2027. With dosing complete in pivotal programs, FDA alignment on BLA strategy, roughly $320M in cash after a recent $200M financing, and a $2.0B market cap, the stock o…
A recent regulatory win for a core aortic product has set the stage for accelerating revenue and margin expansion at Artivion. At roughly $21.83 today and a $1.06B market cap, the stock offers a tradeable long with defined entry, stop and target based on improving fundamentals, reasonable leverage and attractive EV multiples versus expected growth.
Vertex Pharmaceuticals combines a best-in-class cystic fibrosis franchise with deep pipeline optionality, strong free cash flow ($3.71B) and a clean balance sheet. At $500, the stock trades at ~29x 2026 EPS and ~9.9x EV/Sales, pricing reliability into the shares. We outline a long trade with a $500 entry, $620 target and $445 stop for a long-term h…
Westrock Coffee has the hallmarks of a classic turnaround: solid cash generation, a diversified B2B/B2C footprint, and margin levers that can scale with distribution wins. With the stock trading well below reasonable upside and clear catalysts ahead, this is a tactical long for patient traders willing to carry volatility over a 180-trading-day hori…
Costco (COST) looks well positioned to benefit from geopolitical oil-risk and persistent inflation that favor bulk buying and membership retention. The company’s predictable cash flow and pricing power justify a tactical long, but investors must respect a rich valuation and limited upside absent execution beats. Trade plan provided for a mid-term s…
Rocket Lab's announced $8B acquisition of Iridium Communications is a game-changer: it adds a global satellite constellation, recurring service revenue and a path to scale that materially alters Rocket Lab's profile. The stock is a buy here for a mid-term trade based on deal optionality, backlog conversion and upcoming Neutron catalysts, but invest…
Allison Transmission (ALSN) has seen its share price retrace from spring highs as on-highway demand softened. The balance sheet is levered, but the company generates meaningful free cash flow ($609M trailing) and sustains a sizeable buyback program that has meaningfully reduced shares over time. At a market cap near $9.6B and EV/EBITDA ~13.1, the s…
Viridian Therapeutics ($VRDN) just cleared a major regulatory hurdle with the approval of Lumvoa for thyroid eye disease. The stock already reflects some of that upside but remains well below its 52-week high and beneath what a successful launch could justify. This trade idea lays out a mid-term swing entry, precise stop and target levels, and the …
Micron's June quarter results and strategic customer agreements make a compelling near- to medium-term trade: the memory supercycle is real and Micron is the market's clearinghouse for HBM and premium NAND. Valuation looks rich on trailing multiples but earnings and free cash flow are surging. Trade plan below balances upside from continued AI-driv…
Jaguar Mining offers a high-upside trade: management's low-capex plan to double production via brownfield upgrades and processing optimization should materially de-risk the expansion and deliver optionality to re-rate the stock. This trade targets asymmetric reward while protecting downside with a tight stop and defined horizon.
DoorDash is a capital-efficient, founder-led platform that still has room to grow internationally and expand margins in the U.S. After a pullback from 2025 highs, the shares are trading at a valuation that assumes perfection. We like buying a disciplined starter position at $186.53 with a clear stop and a $260 target over the next 180 trading days.
Spyre (SYRE) is a clinical-stage enzyme/antibody company with a diverse immunology pipeline and multiple near-term readouts. The stock trades at $90.15 with a market cap of roughly $7.83B and an expanded cash position after an upsized April offering. Positive SKYLINE Part A data for SPY001 and six Phase 2 readouts expected across 2026 set up clear …
Booking Holdings' diverse portfolio (Booking.com, Priceline, Agoda, KAYAK, OpenTable) and strong cash generation make it a compelling mid-term long. At $182.44, the stock trades at ~23x earnings with roughly $9.0B in free cash flow and an EV/EBITDA near 14. The Iran conflict creates headline volatility but is unlikely to derail global leisure deman…
McEwen (MUX) trades at ~ $18 with a market cap near $1.07B. Recent operational cash from San José, a strong pre-feasibility for Grey Fox, and the latent value of the Los Azules copper project make this a compelling swing trade as investors rotate into copper exposure. I favor a long trade capturing near-term re-rating catalysts while keeping a tigh…
Venture Global (VG) is one of the fastest-scaling U.S. LNG exporters. With recent supply shocks, new long-term contracts, and raised EBITDA guidance, the stock looks like a high-conviction long for patient traders willing to accept execution and leverage risk. I outline an actionable trade with entry, stop and target, plus the catalysts and risks t…
Freehold Royalties offers a 6.8% yield, a $1.86B market cap royalty portfolio across North America and an oversold setup near multi-month support. This trade targets mean reversion toward the 52-week high while collecting monthly distributions; stop discipline is key given commodity sensitivity and elevated short interest.
Costco (COST) is a high-quality, cash-generative business, but at roughly 47-48x earnings the stock already prices in durable double-digit growth. Recent gains were materially helped by elevated gasoline sales; as fuel normalizes, comparable sales growth is likely to decelerate. For traders, that combination argues for a tactical short/sell into st…
Sionna Therapeutics is a clinical-stage biotech developing an NBD1 stabilizer (SION-719) intended to complement standard-of-care CFTR modulators. With Phase 2a topline data expected mid-2026, a relatively well-funded balance sheet and bullish technicals, the stock offers a high-risk, asymmetric swing opportunity. Trade plan: long at $42.96, target …
Frontdoor (FTDR) remains a high-margin, cash-generative home service-plan business — revenue up 14% and record gross margin in recent quarters — but accelerating competitive risk and frothy positioning argue for caution. We downgrade the rating and propose a mid-term short trade to capture a potential re-rating while keeping position size controlle…
Canadian Pacific Kansas City (CP) looks positioned to deliver double-digit EPS growth as cross-border freight demand recovers and network investments translate into higher volumes and pricing power. The company trades at a mid-20s P/E with healthy free cash flow and manageable leverage; we recommend a tactical long with entry at $86.50, stop at $81…
Circle’s USDC business faces a slower circulation backdrop, but higher short-term interest rates and renewed transaction activity (plus regulatory clarity) create an asymmetric risk/reward. The company is cash-flow positive, carries an enterprise value of roughly $17.4B against $296M of free cash flow, and sits well below its 52-week peak. We like …
Tencent is trading near a fresh 52-week low despite solid cash flows, a sub-15 P/E and active AI/content catalysts. The price action has opened a mid-term swing window to buy a beaten-down, cash-generative Chinese tech conglomerate at an attractive risk/reward. Trade plan included.
Artemis Gold looks like a classic mid-cap miner that has moved from project to production and is now using operating cash flow to fund growth. That makes it a rare gold equity that can expand without heavy equity dilution. The trade: buy at $6.50, stop at $4.75, target $9.50 over a mid-term 45 trading day horizon, with a follow-up plan if the compa…
Nano Labs (NA) is a microcap fabless chip and AI infrastructure developer trading at a sub-$50 million market cap, single-digit PE, and low PB. Recent product launches, an MoU for North American AI data centers, and insider buying create a constructive setup. This trade idea outlines a long entry at $1.83 with a $3.50 target and $1.45 stop, sized f…
SiriusPoint looks fundamentally different than it did two years ago. Ratings upgrades, asset de-risking and recent portfolio moves signal a completed operational turnaround. At roughly $24 per share, the market is still pricing the stock like an insurer with elevated tail risk. This trade idea lays out an actionable long with entry, stop and target…
